Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
775.00    0.00 (0.00%)
Bid:
731.00
Ask:
820.00
Spread: 89.00 (12.175%)
Market Cap: £52.70m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Holding(s) in Company

12 Jan 2026 07:00

RNS Number : 4073O
Hemogenyx Pharmaceuticals PLC
12 January 2026
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BQVXM815

Issuer Name

HEMOGENYX PHARMACEUTICALS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

David John Smith

City of registered office (if applicable)

Grimsby

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

Interactive Investor Services Nominees Limited

Manchester

England

Transact Nominees Limited

London

England

HBP Systems Limited

Scunthorpe

England

Kamarin Computers Limited

Scunthorpe

England

HBP Monpellier Limited

Carlisle

England

Copier Systems Limited

Scunthorpe

England

GHC Property Services Limited

Grimsby

England

5. Date on which the threshold was crossed or reached

06-Jan-2026

6. Date on which Issuer notified

09-Jan-2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

7.762000

0.000000

7.762000

468923

Position of previous notification (if applicable)

6.750640

0.000000

6.750640

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BQVXM815

211976

256947

3.508800

4.253200

Sub Total 8.A

468923

7.762000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

David Smith

7.762000

7.762000%

David Smith

GHC Property Services Limited

2.414000

2.414000%

David Smith

HBP Systems Limited

0.459800

0.459800%

David Smith

Kamarin Computers Limited

0.459800

0.459800%

David Smith

HBP Monpellier Limited

0.459800

0.459800%

David Smith

Copier Systems Limited

0.459800

0.459800%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

09-Jan-2026

13. Place Of Completion

Hull, England

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUKUBRNVUARAR
Date   Source Headline
1st Jul 20267:00 amRNSResult of AGM
5th Jun 20267:00 amRNSNotice of AGM
29th May 20269:18 amRNSGrant of Options and Extension of Warrant Term
30th Apr 20264:04 pmRNSFinal Results
28th Apr 20267:00 amRNSInstitutional Fundraise
14th Apr 20267:00 amRNSAnnual IND Report with FDA
31st Mar 20261:22 pmRNSTech Transfer Completion and Clinical Trial Update
27th Feb 20268:10 amRNSTotal Voting Rights
24th Feb 20267:00 amRNSHolding(s) in Company
23rd Feb 20267:00 amRNSExercise of Warrants and Issue of Equity
10th Feb 20263:52 pmRNSIssue of Equity - Correction
10th Feb 20267:00 amRNSIssue of Equity
30th Jan 20267:00 amRNSTotal Voting Rights
12th Jan 20267:00 amRNSHolding(s) in Company
22nd Dec 20258:00 amRNSUpdate on Admission of Shares
18th Dec 20257:00 amRNSIssue of Equity
8th Dec 202512:48 pmRNSHolding(s) in Company
28th Nov 20257:00 amRNSTotal Voting Rights
19th Nov 202511:47 amRNSPublication of Prospectus
29th Oct 20257:00 amRNSClinical Trial Update and Grant of Share Awards
6th Oct 20257:00 amRNSClearance to Initiate Pediatric Enrolment
30th Sep 20257:00 amRNSHalf-year Report
30th Sep 20257:00 amRNSTotal Voting Rights
23rd Sep 20257:00 amRNSHemogenyx Signs Letter of Intent
18th Sep 20251:16 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSThird Patient Safety
11th Sep 20257:00 amRNS-RInvitation to Participate at DCNY Summit
8th Sep 20257:00 amRNSManufacturing Partnership with Made Scientific
5th Sep 20257:00 amRNSExercise of Warrants and Issue of Equity
3rd Sep 20251:57 pmRNSExercise of Warrants and Issue of Equity
1st Sep 20253:06 pmRNSIssue of convertible loan notes
29th Aug 20257:00 amRNSResult of Audit Tender
26th Aug 202511:44 amRNSHemogenyx raises £570,000 and Director's Dealing
15th Aug 20257:00 amRNSThird Patient Treated with HG-CT-1 CAR-T Therapy
31st Jul 20257:00 amRNSTotal Voting Rights
29th Jul 20258:00 amRNSPlacing to Raise £250,000 and Director’s Dealing
16th Jul 20257:00 amRNSHemogenyx Awarded Grant
30th Jun 20257:00 amRNSTotal Voting Rights
17th Jun 20257:00 amRNSClearance to Proceed with Pediatric Expansion
3rd Jun 20252:02 pmRNSPlacing to Raise £451,250 and Director’s Dealing
3rd Jun 20257:00 amRNSSecond Patient Passes Initial Safety Tests
30th May 20253:14 pmRNSTotal Voting Rights
29th May 20252:06 pmRNSResult of AGM
14th May 20257:00 amRNS-RPediatric Amendment to Clinical Protocol
13th May 20257:00 amRNSAGM Correction
8th May 20257:00 amRNSPlacing to Raise £451,250 and Director’s Dealing
2nd May 20254:24 pmRNSNotice of AGM
2nd May 20257:00 amRNSSecond Patient Treated with HG-CT-1 CAR-T Therapy
28th Apr 20257:00 amRNSFinal Results
3rd Apr 20257:00 amRNS-RFDA Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.